story of the week
Pembrolizumab vs Investigator-Choice Chemotherapy for Metastatic Triple-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab Versus Investigator-Choice Chemotherapy for Metastatic Triple-Negative Breast Cancer (KEYNOTE-119): A Randomised, Open-Label, Phase 3 Trial
Lancet Oncol 2021 Mar 04;[EPub Ahead of Print], EP Winer, O Lipatov, SA Im, A Goncalves, E Muñoz-Couselo, KS Lee, P Schmid, K Tamura, L Testa, I Witzel, S Ohtani, N Turner, S Zambelli, N Harbeck, F Andre, R Dent, X Zhou, V Karantza, J Mejia, J CortesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.